X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4954) 4954
Newsletter (27) 27
Magazine Article (10) 10
Book Chapter (4) 4
Book Review (4) 4
Publication (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
Newspaper Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3229) 3229
clarithromycin (2864) 2864
pharmacology & pharmacy (2437) 2437
anti-bacterial agents - pharmacology (1848) 1848
clarithromycin - pharmacology (1707) 1707
male (1661) 1661
female (1547) 1547
microbiology (1475) 1475
microbial sensitivity tests (1199) 1199
adult (1137) 1137
middle aged (1055) 1055
helicobacter pylori - drug effects (1052) 1052
anti-bacterial agents - therapeutic use (1001) 1001
helicobacter infections - drug therapy (968) 968
helicobacter pylori (903) 903
infection (897) 897
clarithromycin - therapeutic use (866) 866
aged (814) 814
infectious diseases (801) 801
animals (723) 723
azithromycin (633) 633
gastroenterology & hepatology (628) 628
drug therapy, combination (613) 613
helicobacter infections - microbiology (587) 587
amoxicillin (582) 582
antibiotics (582) 582
erythromycin (581) 581
clarithromycin - administration & dosage (549) 549
anti-bacterial agents - administration & dosage (529) 529
drug resistance, bacterial (526) 526
treatment outcome (496) 496
metronidazole (479) 479
eradication (477) 477
adolescent (465) 465
erythromycin - pharmacology (417) 417
resistance (405) 405
macrolides (397) 397
helicobacter pylori - isolation & purification (392) 392
therapy (390) 390
susceptibility (380) 380
pharmacokinetics (370) 370
mice (359) 359
helicobacter pylori - genetics (353) 353
metronidazole - pharmacology (332) 332
drug interactions (319) 319
prevalence (318) 318
in-vitro (317) 317
omeprazole (316) 316
antibiotic-resistance (311) 311
amoxicillin - pharmacology (308) 308
drug resistance, microbial (308) 308
azithromycin - pharmacology (301) 301
aged, 80 and over (298) 298
bacterial infections and mycoses (298) 298
triple therapy (298) 298
anti-bacterial agents - adverse effects (296) 296
child (296) 296
infections (293) 293
amoxicillin - therapeutic use (286) 286
efficacy (283) 283
clarithromycin - adverse effects (270) 270
research article (261) 261
antimicrobial resistance (251) 251
anti-bacterial agents - pharmacokinetics (248) 248
levofloxacin (245) 245
anti-ulcer agents - therapeutic use (240) 240
clarithromycin resistance (240) 240
drug resistance (235) 235
clarithromycin - pharmacokinetics (225) 225
amoxicillin - administration & dosage (224) 224
strains (224) 224
erythromycin - analogs & derivatives (222) 222
prospective studies (219) 219
antimicrobial agents (218) 218
analysis (213) 213
dose-response relationship, drug (212) 212
bacteria (206) 206
macrolide antibiotics (206) 206
lansoprazole (202) 202
omeprazole - therapeutic use (201) 201
fluoroquinolones (200) 200
management (200) 200
drug administration schedule (199) 199
rna, ribosomal, 23s - genetics (199) 199
young adult (199) 199
time factors (198) 198
children (194) 194
mutation (194) 194
administration, oral (192) 192
drug resistance, bacterial - genetics (189) 189
proton pump inhibitors (189) 189
immunology (186) 186
macrolides - pharmacology (184) 184
research (184) 184
health aspects (183) 183
child, preschool (182) 182
drug resistance in microorganisms (182) 182
medicine & public health (182) 182
disease (180) 180
macrolide (179) 179
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4804) 4804
Japanese (316) 316
Spanish (54) 54
Chinese (28) 28
French (26) 26
Portuguese (21) 21
German (13) 13
Russian (8) 8
Korean (6) 6
Italian (4) 4
Turkish (4) 4
Dutch (3) 3
Polish (3) 3
Hungarian (2) 2
Romanian (2) 2
Czech (1) 1
Danish (1) 1
Hebrew (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
by Fong, P and Hao, CH and Io, CC and Sin, PI and Meng, LR
MOLECULES, ISSN 1420-3049, 10/2019, Volume 24, Issue 19, p. 3608
Journal Article
Antimicrobial agents and chemotherapy, ISSN 0066-4804, 04/2016, Volume 60, Issue 4, pp. 1974 - 1983
In this study, we tested five compounds belonging to a novel series of piperazine arylideneimidazolones for the ability to inhibit the AcrAB-TolC efflux pump.... 
MICROBIOLOGY | PHARMACOLOGY & PHARMACY | 5-ARYLIDENE AROMATIC DERIVATIVES | MULTIDRUG-RESISTANCE | IDENTIFICATION | PSEUDOMONAS-AERUGINOSA | Fluorescent Dyes - chemical synthesis | Protein Kinases - metabolism | Protein Kinases - genetics | Escherichia coli - drug effects | Cephalosporins - chemistry | Levofloxacin - pharmacology | Repressor Proteins - antagonists & inhibitors | Microbial Sensitivity Tests | Membrane Transport Proteins - genetics | Escherichia coli - metabolism | Linezolid - pharmacology | Biological Assay | Fluorescent Dyes - pharmacology | Membrane Transport Proteins - metabolism | Biological Transport - drug effects | Cell Membrane - metabolism | Membrane Proteins - metabolism | Escherichia coli - growth & development | Escherichia coli Proteins - antagonists & inhibitors | Imidazoles - chemical synthesis | Indicators and Reagents - chemistry | Bacterial Outer Membrane Proteins - antagonists & inhibitors | Bacterial Outer Membrane Proteins - genetics | Cell Membrane - drug effects | Repressor Proteins - metabolism | Gene Expression | Membrane Proteins - genetics | Oxacillin - pharmacology | Repressor Proteins - genetics | Escherichia coli Proteins - metabolism | Imidazoles - pharmacology | Piperazines - pharmacology | Anti-Bacterial Agents - chemical synthesis | Drug Synergism | Bacterial Outer Membrane Proteins - metabolism | Membrane Proteins - antagonists & inhibitors | Escherichia coli - genetics | Escherichia coli Proteins - genetics | Piperazines - chemical synthesis | Anti-Bacterial Agents - pharmacology | Kinetics | Rifampin - pharmacology | Clarithromycin - pharmacology
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 2013, Volume 76, Issue 3, pp. 455 - 466
Aims The anticoagulant rivaroxaban is an oral, direct Factor Xa inhibitor for the management of thromboembolic disorders. Metabolism and excretion involve... 
P‐glycoprotein | rivaroxaban | drug interactions | cytochrome P450 | healthy subjects | P-glycoprotein | Rivaroxaban | Healthy subjects | Cytochrome P450 | Drug interactions | BAY-59-7939 | SAFETY | PREVENTION | PHARMACODYNAMICS | PROTEASE INHIBITORS | IN-VITRO | FACTOR-XA INHIBITOR | ERYTHROMYCIN | PHARMACOLOGY & PHARMACY | LIVER-MICROSOMES | Anticoagulants - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Erythromycin - pharmacology | Ketoconazole - administration & dosage | Humans | Middle Aged | Cytochrome P-450 Enzyme System - metabolism | Midazolam - administration & dosage | Substrate Specificity | Metabolic Clearance Rate | Thiophenes - administration & dosage | Ketoconazole - pharmacology | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Clarithromycin - pharmacokinetics | Clarithromycin - administration & dosage | Adult | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Ketoconazole - pharmacokinetics | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A - administration & dosage | Erythromycin - administration & dosage | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Thiophenes - pharmacokinetics | Erythromycin - pharmacokinetics | Cytochrome P-450 CYP3A - metabolism | Adolescent | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Clarithromycin - pharmacology | Midazolam - pharmacology | Ketoconazole | Protease inhibitors | Fluconazole | Proteases | Cytochrome P-450 | Dosage and administration | Anticoagulants (Medicine) | Erythromycin | Thromboembolism
Journal Article
Antimicrobial agents and chemotherapy, ISSN 0066-4804, 12/2015, Volume 59, Issue 12, pp. 7497 - 7503
Journal Article